Affiliation:
1. Myeloma Center University of Arkansas for Medical Sciences Little Rock Arkansas USA
2. Department of Internal Medicine University of Jordan Amman Jordan
Abstract
AbstractTalquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post‐treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post‐discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.
Reference7 articles.
1. U.S. FDA approves TALVEY™ (talquetamab‐tgvs) a first‐in‐class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. Accessed March 12 2024.https://www.jnj.com/media‐center/press‐releases/u‐s‐fda‐approves‐talvey‐talquetamab‐tgvs‐a‐first‐in‐class‐bispecific‐therapy‐for‐the‐treatment‐of‐patients‐with‐heavily‐pretreated‐multiple‐myeloma
2. Targeting GPRC5D in multiple myeloma
3. Perspectives on the Treatment of Multiple Myeloma
4. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
5. Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss